Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Sulbactam Sodium

FDA-approved product (injectable, injection).

Registered studies
50+
Lab records
20
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Sulbactam Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Beta-lactamase inhibitors
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01CG01

Repurposing investigation

Sulbactam Sodium is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA6.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli64.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae18.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis26.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 2 of 5 lab records
  • E. coli: measured active in 10 of 13 lab records
  • K. pneumoniae: measured active in 0 of 2 lab records
Open Sulbactam Sodium in ChEMBL Registered studies below
Show the 20 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-4.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-5.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-4.6 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Sulbactam Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Special Use-Result Surveillance of Unasyn-S (Kit) for Intravenous Use - A Surveillance on High-dose (>6 g Daily) Administration -

    NCT01793688 · start 2013-03-12

    Registered record
    Registry ID
    NCT01793688
    Conditions
    Pneumonia; Lung Abscess; Peritonitis
    Interventions
    Sulbactam Sodium/Ampicillin Sodium
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2013-03-12
    Completion
    2016-01-27
    Enrolment
    982

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPneumonia; Lung Abscess; Peritonitis
    InterventionSulbactam Sodium/Ampicillin Sodium
    PhaseNot recorded
    Registry statusCompleted

  • Study on Ceftazidime and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection

    NCT01601093 · start 2011-11

    Registered record
    Registry ID
    NCT01601093
    Conditions
    Respiratory Tract Infections; Urinary Tract Infections
    Interventions
    High dose; Low dose; Cefoperazone and Sulbactam Sodium (CFP/SUB)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Suspended
    Start
    2011-11
    Completion
    2022-12-15
    Enrolment
    288

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRespiratory Tract Infections; Urinary Tract Infections
    InterventionHigh dose; Low dose; Cefoperazone and Sulbactam Sodium (CFP/SUB)
    PhasePhase 2
    Registry statusSuspended

  • Study on Cefotaxime and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection

    NCT01426191 · start 2011-08

    Registered record
    Registry ID
    NCT01426191
    Conditions
    Respiratory Tract Infections; Urinary Tract Infections
    Interventions
    xinzhijun
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2011-08
    Completion
    2016-12
    Enrolment
    2,032

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRespiratory Tract Infections; Urinary Tract Infections
    Interventionxinzhijun
    PhaseNot recorded
    Registry statusCompleted

  • Piperacillin Sodium and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection

    NCT01897831 · start 2011-08

    Registered record
    Registry ID
    NCT01897831
    Conditions
    Respiratory Tract Infections; Urinary Tract Infections
    Interventions
    xin te mie
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2011-08
    Completion
    2015-11
    Enrolment
    2,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRespiratory Tract Infections; Urinary Tract Infections
    Interventionxin te mie
    PhasePhase 4
    Registry statusUnknown

  • Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) for Treatment of Respiratory and Urinary System Infection

    NCT01760109 · start 2011-07

    Registered record
    Registry ID
    NCT01760109
    Conditions
    Respiratory Tract Infections; Urinary Tract Infections
    Interventions
    Piperacillin Sodium and Sulbactam Sodium
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-07
    Completion
    2016-06
    Enrolment
    2,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRespiratory Tract Infections; Urinary Tract Infections
    InterventionPiperacillin Sodium and Sulbactam Sodium
    PhasePhase 4
    Registry statusCompleted

  • Asymptomatic Bacteriuria & Risk of Urinary Tract Infection in Renal Transplants

    NCT01349738 · start 2011-05

    Registered record
    Registry ID
    NCT01349738
    Conditions
    Bacteriuria; Urinary Tract Infections; Asymptomatic Infections; Transplantation Infection
    Interventions
    Antibiotic
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2011-05
    Completion
    2013-05
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacteriuria; Urinary Tract Infections; Asymptomatic Infections; Transplantation Infection
    InterventionAntibiotic
    PhaseNot recorded
    Registry statusUnknown

  • Antibiotic Prophylaxis for Early Ventilator-associated Pneumonia in Neurological Patients

    NCT01118403 · start 2011-03

    Registered record
    Registry ID
    NCT01118403
    Conditions
    Ventilator Associated Pneumonia
    Interventions
    Sultamicillin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2011-03
    Completion
    2011-03
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVentilator Associated Pneumonia
    InterventionSultamicillin
    PhasePhase 4
    Registry statusWithdrawn

  • An Open-label, Randomized, and Comparative Study to Evaluate the Efficacy and Safety of Cefoperazone/Sulbactam in Comparison to Cefepime for the Treatment of Hospital-acquired Pneumonia and Healthcare-associated Pneumonia

    NCT01280461 · start 2010-07

    Registered record
    Registry ID
    NCT01280461
    Conditions
    Pneumonia
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2010-07
    Completion
    2011-12
    Enrolment
    142

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPneumonia
    InterventionNot recorded
    PhaseNot recorded
    Registry statusUnknown

  • Ampicillin / Sulbactam vs. Ampicillin / Gentamicin for Treatment of Chorioamnionitis

    NCT00879190 · start 2009-05

    Registered record
    Registry ID
    NCT00879190
    Conditions
    Chorioamnionitis
    Interventions
    Unasyn; Ampicillin/gentamicin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2009-05
    Completion
    2012-06
    Enrolment
    92

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChorioamnionitis
    InterventionUnasyn; Ampicillin/gentamicin
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • A Comparative Study of Ampicillin/Sulbactam Versus Moxifloxacin in the Treatment of Complicated Intra-abdominal Infections

    NCT00952796 · start 2009-01

    Registered record
    Registry ID
    NCT00952796
    Conditions
    Intra-abdominal Infection
    Interventions
    moxifloxacin; ampicillin/sulbactam
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-01
    Completion
    2010-12
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIntra-abdominal Infection
    Interventionmoxifloxacin; ampicillin/sulbactam
    PhasePhase 4
    Registry statusCompleted

  • Preventing Complications in Cleft Palate Repair With Antibiotics

    NCT00760006 · start 2008-05

    Registered record
    Registry ID
    NCT00760006
    Conditions
    Cleft Palates
    Interventions
    Unasyn; saline solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-05
    Completion
    2015-08
    Enrolment
    224

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCleft Palates
    InterventionUnasyn; saline solution
    PhasePhase 2
    Registry statusCompleted

  • Ampicillin-sulbactam Resistant E.Coli at UPMC

    NCT00619580 · start 2008-02

    Registered record
    Registry ID
    NCT00619580
    Conditions
    Positive E Coli Infections
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Withdrawn
    Start
    2008-02
    Completion
    2014-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPositive E Coli Infections
    InterventionNot recorded
    PhaseNot recorded
    Registry statusWithdrawn

  • Cefoperazone/Sulbactam In The Treatment Of Serious Intra-Abdominal And Hepatobiliary Infections.

    NCT00463762 · start 2007-05

    Registered record
    Registry ID
    NCT00463762
    Conditions
    Abscess, Intra-Abdominal; Cholecystitis; Wound Infections; Peritonitis; Appendicitis
    Interventions
    CP-75385-02 Cefoperazone/sulbactam
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Withdrawn
    Start
    2007-05
    Completion
    Not recorded
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAbscess, Intra-Abdominal; Cholecystitis; Wound Infections; Peritonitis +1 more
    InterventionCP-75385-02 Cefoperazone/sulbactam
    PhaseNot recorded
    Registry statusWithdrawn

  • A Comparative Phase IV Study Evaluating Efficacy & Safety Of Magnex(Cefoperazone-Sulbactam) In Intraabdominal Infections

    NCT00360607 · start 2004-07

    Registered record
    Registry ID
    NCT00360607
    Conditions
    Infection
    Interventions
    Magnex (Sulbactam Sodium/Cefoperazone Sodium 1:1) Pfizer Ltd.; Fortum (Ceftazidime for injection USP) Glaxo Smith Kline Pharmaceuticals Limited; Metrogyl (Metronidazole Injection IP) J.B.Chemicals & Pharmaceuticals Ltd.; Mikacin (Amikacin Sulphate Injection IP) Aristo Pharmaceuticals Ltd.
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2004-07
    Completion
    2005-04
    Enrolment
    307

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection
    InterventionMagnex (Sulbactam Sodium/Cefoperazone Sodium 1:1) Pfizer Ltd.; Fortum (Ceftazidime for injection USP) Glaxo Smith Kline Pharmaceuticals Limited; Metrogyl (Metronidazole Injection IP) J.B.Chemicals & Pharmaceuticals Ltd.; Mikacin (Amikacin Sulphate Injection IP) Aristo Pharmaceuticals Ltd.
    PhasePhase 4
    Registry statusCompleted

  • Ampicillin/Sulbactam Versus Cefuroxime as Antimicrobial Prophylaxis for Cesarean Section

    NCT01138852 · start 2004-07

    Registered record
    Registry ID
    NCT01138852
    Conditions
    Surgical Site Infections
    Interventions
    Ampicillin-sulbactam; Cefuroxime
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2004-07
    Completion
    2008-12
    Enrolment
    176

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSurgical Site Infections
    InterventionAmpicillin-sulbactam; Cefuroxime
    PhasePhase 4
    Registry statusCompleted